Fig. 8
From: Polymeric nanomedicines for the treatment of hepatic diseases
(Reprinted with permission from Ref. [184], Copyright 2019, American Chemical Society)
A Preparation of GC-FU/miR-122 and hepatoma-targeted codelivery of miR-122 and 5-Fu. B Viability of HepG2 cells after incubation with various treatment constructs. C The expression of Bcl-2 and ADAM17 in the HepG2 cells and quantitative analysis.